Tokyo, June 23, 2006 (JCN) - Toyama Chemical has commenced phase I clinical trials of T-5224, its proprietary drug candidate for the treatment of rheumatoid arthritis (RA). A low-molecular compound that inhibits an activator protein 1 (AP-1), T-5224 alleviates inflammation and joint destruction so it is expected to be used as a basic remedy for RA.
